RNA therapy for neurodegenerative, cardiac, and pulmonary disease
ASO therapeutic targeting MEG3 for neurodegenerative diseases, including Alzheimer's.
MEG3 is a long non-coding RNA, implicated in Neurodegenerative, cardiac, and pulmonary disease. In Alzheimer’s disease a knockdown model was shown to have reduced necroptosis. The technology is oligonucleotide-based therapies to target the transcript.
Applications: Therapeutics, RNA therapies, Neurodegenerative diseases
| Features | Benefits |
|---|---|
| Targets MEG3 | Implicated in neurodegenerative, cardiac, and pulmonary disease |
| Can reduce MEG3 expression to 5% or lower | Optimise expression level |
| Efficacy in gapmer and siRNA formats | Multiple approaches to suit disease and technology |
| Reduces necroptosis | Targets main driver of AD pathology |
Patented and Available For
- Co-development
- Consulting
- Licensing